06.03.2008 17:18:00
|
Joffe Announces Board Nominees for 2008 TLC Vision Shareholder Meeting
Dr. Stephen N. Joffe, a Cincinnati investor and laser vision correction
industry pioneer who holds 5% of the shares of TLC Vision Corporation
(NasdaqGS:TLCV), has delivered written notice to TLC Vision for the
nominations of Michael R. Henderson, Cathy Willis and himself to stand
for election as a minority slate of directors at the 2008 annual meeting
of shareholders.
Additionally, Dr. Joffe has requested that the TLC Vision board
immediately appoint one of his nominees to fill a long-vacant seat on
the company’s board, and endorse that nominee’s
election to a full term. Should they fail to do this, Dr. Joffe demands
that the Board explain its rationale and provide details on the
decision-making criteria it uses to select Board members.
TLC Vision operates approximately 80 refractive centers in the U.S. and
Canada. Dr. Joffe is the founder and past CEO of LCA-Vision, Inc.,
parent company of LasikPlus, TLC Vision’s
largest competitor. He has no current relationship with LCA-Vision, Inc.
Dr. Joffe stated, "Having built the most successful company in this
industry, I understand it will take a knowledgeable and experienced
leadership team to turn TLC Vision around. Michael Henderson and Cathy
Willis possess the insight and requisite business acumen to help me fix
the vast number of critical operational and financial issues facing the
company.”
Dr. Joffe ended his affiliation with Cincinnati-based LCA-Vision, Inc.
(Nasdaq: LCAV), in early 2006. During his 10-year tenure as the company’s
founder, chairman and CEO, he created a company whose market value
dwarfed that of TLC Vision and returned more that 4,000 percent to
shareholders. The value of LCA-Vision’s shares
have fallen more than 75% percent since his February 2006 departure as
the company’s CEO.
Mr. Henderson also possesses significant refractive industry experience,
having served as president and CEO of publicly traded LVC (Laser Vision
Centers) Corporation from 1996 to 2000. During his tenure at LVC annual
revenues grew from under $2 million to $85 million in 36 months.
Ms. Willis is a founder of Felton Willis, LLC, a market research firm
that specializes in healthcare-related matters on behalf of both
pharmaceutical and consumer products companies. She also offers
extensive corporate marketing experience, having served in key
managerial positions at P&G.
In a letter to TLC Vision chairman Warren S. Rustand and the entire TLC
Vision board dated March 6, 2008, and filed with Dr. Joffe’s
amended Schedule 13D today, Dr. Joffe stated: "If
I do not receive verification in writing by Monday, March 10, 2008, that
the Corporation will include the Director Nominees in its proxy
materials for the 2008 Annual Meeting of Shareholders, I will proceed to
make other arrangements to give effect to my minority slate of Director
Nominees. I intend to file proxy materials with the Securities and
Exchange Commission and solicit proxies for the Director Nominees and to
vigorously pursue the election of the Director Nominees at the 2008
Annual Meeting of Shareholders.”
Dr. Joffe has called on the TLC Vision Board to create a leadership team
that can effectively lead. "TLC shareholders
have witnessed almost two-thirds of the company’s
value disappear in the past year. We deserve better,”
he said. "We deserve a board that will speak
up for the shareholders it represents. We deserve a board that is not
afraid to fix what is broken. We deserve a board that understands the
meaning of leadership, and the responsibilities that accompany it.”
The full text of the letter appears below.
About Stephen N. Joffe Stephen N. Joffe, MD, FACS, FCS (SA), FRCS, age 65, is past
Chairman of the Board and Chief Executive Officer of LCA-Vision. He was
the founder of the Company’s corporate
predecessor, Laser Centers of America, Inc., and served as its Chairman
of the Board and Chief Executive Officer from its formation in 1985
until its merger into LCA-Vision in 1995. In 1983, Stephen Joffe also
founded and served as Chairman of Surgical Laser Technologies, Inc.
until 1989. He is presently the Chief Executive Officer of the Joffe
Foundation, a non-profit charity and Co-Chairman of Joffe LLC, a
healthcare services company. In addition, Dr. Joffe is an Esteemed
Quondam Professor of Surgery at the University of Cincinnati Medical
Center, an honor he has held since 1990. He has held other medical
faculty appointments at the Universities of London, Glasgow and
Cincinnati and fellowships in the American College of Surgeons and the
Royal College of Surgeons of Edinburgh and Glasgow. He has published 170
articles in peer-reviewed and scientific journals and authored 35
chapters for medical books as well as written and edited several books
on lasers and their application to medicine and surgery.
About Michael R. Henderson Michael R. Henderson, age 45, has served as Chairman and Chief
Executive Officer of Moon World Resorts Inc., a private company in
Vancouver, Canada, since May of 2000. Mr. Henderson devised and designed
this major mega-resort and real estate development, which employs a
global team of 120 sales and creative professionals, including a group
of top-tier architects and engineers. Earlier, Mr. Henderson was
President and CEO of LVC (Laser Vision Centers) Corporation, a public
company (TSXV), from 1996 to 2000. While he led LVC Corporation, its
revenues grew from $1.2 million to $85 million in 36 months. LVC
Corporation became one of the fastest growing surgical companies with a
staff that grew from six to over 450. Mr. Henderson directed 31 clinic
build-outs, 28 additional planned build-outs, and successfully took the
company public after raising over $30 million in private equity
financing. Before joining LVC Corporation, Mr. Henderson served as
Division President of Rentokil Initial PLC, a public company (LSE), from
1991 to 1996 where he built a powerful sales team across Canada. Prior
to Rentokil, from 1983 to 1991, he was the Divisional Manager of the
Phillips Distribution Auto Group, a private company in Ireland where he
posted many sales records. Mr. Henderson is a target-orientated,
seasoned management professional with considerable experience in all
business areas – including concept design,
product, marketing, sales, service, investor relations, public
relations, human resources and overall corporate development. He is a
highly organized team player with a results-focused approach.
About Cathy Willis Cathy Willis, age 52, has over 30 years of marketing and
marketing research experience, both on the corporate side as a Brand
Manager and Marketing Director and as co-founder of Felton Willis, LLC,
a qualitative research and strategy development company. Ms. Willis was
a Marketing Director in Pharmaceuticals at Procter & Gamble, with direct
responsibility for women’s health, GI and
anti-infective products. She also had extensive marketing experience at
P&G developing targeted marketing programs for a range of consumer
products such as diapers, feminine care, skin care, oral care and
food/nutritional products. In 1998, Ms. Willis co-founded Felton Willis,
LLC. The company offers full-service qualitative research to a range of
blue-chip clients, including "Fortune 500”
consumer product and pharmaceutical companies. Her focus is primarily on
all aspects of health care, both understanding the healthcare consumer
and the key medical decision-makers -- MDs, nurses, and managed care
professionals. She is a graduate of Miami University with a degree in
English/Journalism.
Letter from Stephen Joffe to TLC Vision Corporation Board
March 6, 2008
Mr. Warren S. Rustand, Chairman
TLC Vision Corporation
TLC Vision Corporation
16305 Swingley Ridge Road
5280 Solar Drive, Suite 100
Suite 300
Mississauga, Ontario
St. Louis, Missouri 63017
L4W 5M8 Canada
Dear Warren:
Accompanying this letter is a formal nomination to the Board of
Directors of TLC Vision Corp. (the "Corporation”)
of Stephen N. Joffe, Michael R. Henderson and Cathy Willis
(collectively, the "Director Nominees”).
As I am certain that you and your Board of Directors will agree, each of
these Director Nominees offers impressive credentials:
Stephen N. Joffe, MD, FACS, FCS (SA), FRCS, age 65, is past
Chairman of the Board and Chief Executive Officer of LCA-Vision. He was
the founder of the Company’s corporate
predecessor, Laser Centers of America, Inc., and served as its Chairman
of the Board and Chief Executive Officer from its formation in 1985
until its merger into LCA-Vision in 1995. In 1983, Stephen Joffe also
founded and served as Chairman of Surgical Laser Technologies, Inc.
until 1989. He is presently the Chief Executive Officer of the Joffe
Foundation, a non-profit charity and Co-Chairman of Joffe LLC, a
healthcare services company. In addition, Dr. Joffe is an Esteemed
Quondam Professor of Surgery at the University of Cincinnati Medical
Center, an honor he has held since 1990. He has held other medical
faculty appointments at the Universities of London, Glasgow and
Cincinnati and fellowships in the American College of Surgeons and the
Royal College of Surgeons of Edinburgh and Glasgow. He has published 170
articles in peer-reviewed and scientific journals and authored 35
chapters for medical books as well as written and edited several books
on lasers and their application to medicine and surgery.
Michael R. Henderson, age 45, has served as Chairman and Chief
Executive Officer of Moon World Resorts Inc., a private company in
Vancouver, Canada, since May of 2000. Mr. Henderson devised and designed
this major mega-resort and real estate development, which employs a
global team of 120 sales and creative professionals, including a group
of top-tier architects and engineers. Earlier, Mr. Henderson was
President and CEO of LVC (Laser Vision Centers) Corporation, a public
company (TSXV), from 1996 to 2000. While he led LVC Corporation, its
revenues grew from $1.2 million to $85 million in 36 months. LVC
Corporation became one of the fastest growing surgical companies with a
staff that grew from six to over 450. Mr. Henderson directed 31 clinic
build-outs, 28 additional planned build-outs, and successfully took the
company public after raising over $30 million in private equity
financing. Before joining LVC Corporation, Mr. Henderson served as
Division President of Rentokil Initial PLC, a public company (LSE), from
1991 to 1996 where he built a powerful sales team across Canada. Prior
to Rentokil, from 1983 to 1991, he was the Divisional Manager of the
Phillips Distribution Auto Group, a private company in Ireland where he
posted many sales records. Mr. Henderson is a target-orientated,
seasoned management professional with considerable experience in all
business areas – including concept design,
product, marketing, sales, service, investor relations, public
relations, human resources and overall corporate development. He is a
highly organized team player with a results-focused approach.
Cathy Willis, age 52, has over 30 years of marketing and
marketing research experience, both on the corporate side as a Brand
Manager and Marketing Director and as co-founder of Felton Willis, LLC,
a qualitative research and strategy development company. Ms. Willis was
a Marketing Director in Pharmaceuticals at Procter & Gamble, with direct
responsibility for women’s health, GI and
anti-infective products. She also had extensive marketing experience at
P&G developing targeted marketing programs for a range of consumer
products such as diapers, feminine care, skin care, oral care and
food/nutritional products. In 1998, Ms. Willis co-founded Felton Willis,
LLC. The company offers full-service qualitative research to a range of
blue-chip clients, including "Fortune 500”
consumer product and pharmaceutical companies. Her focus is primarily on
all aspects of health care, both understanding the healthcare consumer
and the key medical decision-makers -- MDs, nurses, and managed care
professionals. She is a graduate of Miami University with a degree in
English/Journalism.
As previously disclosed in my Schedule 13D filings, I beneficially own
in excess of 5% of the outstanding common shares of the Corporation.
Therefore, I am nominating the Director Nominees pursuant to the
Corporation’s Articles of Incorporation, as
amended, which permit beneficial owners of 5% or more of the outstanding
common shares to nominate directors. I note the Corporation’s
public disclosure in its filings, with the Securities and Exchange
Commission and otherwise, provides that such owners can nominate persons
to serve as directors (which includes a requirement that nominees be
named in the Corporation’s proxy materials
for the next annual meeting of shareholders). I further understand that
the nomination is being made in a timely fashion, at least 90 days prior
to the anniversary date of the 2007 Annual Meeting of Shareholders.
I request that you verify in writing to me no later than the close of
business on Monday, March 10, 2008, that you will include the Director
Nominees in the Corporation’s proxy materials
for its 2008 Annual Meeting of Shareholders. I understand that the Board
has a previously scheduled meeting for the date of this letter and the
following day, so a timely written response from the Corporation is both
feasible and in the best interests of all of the shareholders of the
Corporation.
If I do not receive verification in writing by Monday, March 10, 2008,
that the Corporation will include the Director Nominees in its proxy
materials for the 2008 Annual Meeting of Shareholders, I will proceed to
make other arrangements to give effect to my minority slate of Director
Nominees. I intend to file proxy materials with the Securities and
Exchange Commission and solicit proxies for the Director Nominees and to
vigorously pursue the election of the Director Nominees at the 2008
Annual Meeting of Shareholders.
Given the fact that one director has resigned since being elected at the
2007 Annual Meeting of Shareholders (creating a vacancy) and the fact
that the Board has apparently not identified a suitable and qualified
successor, the Board should consider immediately nominating one of the
Director Nominees to the Board immediately. Otherwise, the Corporation
is obligated to communicate to the shareholders the reasons why at least
one of the Director Nominees is not qualified both to be added to the
Board immediately to fill the existing vacancy and to be recommended by
the Board for re-election at the 2008 Annual Meeting of Shareholders. I
note the Corporation’s discussion in the
proxy materials for its 2007 Annual Meeting of Shareholders that "[t]here
are no differences in the manner in which the [Corporation’s]
Nominating and Corporate Governance Committee will review and consider
director nominees recommended by shareholders.”
Given the obvious credentials of the Director Nominees, which are at
least on par with all of the current directors, if the Board both
rejected my nomination of the Director Nominees and chose not to
nominate the Director Nominees by its own action, all of the
shareholders and I would be interested to learn more about the criteria
utilized by the Board in evaluating potential nominees.
I look forward to hearing from you by March 10, 2008.
Sincerely,
Stephen N. Joffe
cc:
TLC Vision Corporation Board of Directors
James Wachtman, C.E.O.
Michael DePaolis, O.D.
Richard Lindstrom, M.D.
Toby S. Wilt
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu TLC Laser Eye Center Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu TLC Laser Eye Center Inc.mehr Analysen
Indizes in diesem Artikel
NASDAQ Comp. | 19 478,88 | -0,06% |